At Prosemble,
we are redefining cancer treatment…
through groundbreaking innovation in nanotechnology and AI-driven drug delivery. As a spin-out from King’s College London, with a world-class team of scientists, AI specialists, and industry leaders, we are committed to pioneering breakthrough treatments that bring hope to millions.
Company History
Prosemble’s journey began as a compelling story of resilience, transformative change, serendipitous encounters, and pioneering scientific innovation
It all started when Dr. Julien Bergeron, then a postdoctoral researcher at the University of Washington School of Medicine in Seattle, working in the lab of Professor Justin Kollman, first encountered a previously unknown bacterial protein. Although the team recognised its potential for use in targeted drug delivery, they were unable to determine its structure at the time. Years later, at King’s College London, Dr. Bergeron revisited the protein—named BeeR—applying advanced imaging techniques. With the support of a talented team including Dr. Alexandra Parker, Shamar Lale-Farjat, Hanna Lewicka, and Chloe Parry, he discovered that in the presence of ATP, BeeR assembled into three strands forming a hollow tubular structure. Though its biological function remained elusive, the discovery of an actin-like protein forming such a structure offered a transformative insight into the evolution of this important protein family.
Despite a groundbreaking scientific breakthrough, the team lacked the commercial expertise required to bring their innovation to market. Then, a series of extraordinary and seemingly destined events began to unfold. In 2022, Ukrainian scientist Iryna Peretiazhko arrived in the UK through the Ukraine Sponsorship Scheme, fleeing the war with little more than hope—seeking both housing and employment. At the same time, Inna Zhuranskaya, a seasoned private equity executive with deep expertise in biotech and leadership experience at Alkor Bio Group and Astra Biotech GmbH, was actively involved in refugee resettlement efforts. Through these efforts, Inna and Iryna crossed paths. Iryna soon joined Dr Bergeron’s laboratory and, recognising Inna’s exceptional commercial acumen, introduced her to the team—who quickly realised she would become a pivotal force in the venture.
That fortuitous introduction led to the founding of Prosemble, a spin-out from King’s College London. Bringing together scientific ingenuity and commercial expertise, Prosemble quickly positioned itself at the forefront of medical innovation. Today, the company pioneers the use of AI and nanotechnology to transform drug delivery and redefine the future of cancer treatment.
Mission & Vision
At Prosemble, our mission is to revolutionise cancer treatment by integrating advanced nanoparticle technology and artificial intelligence, ensuring more effective therapies with fewer side effects.
We believe in a future where precision medicine is not just an ambition but a reality, where every patient receives the right treatment at the right time, maximising efficacy while minimising harm.
Our vision is to lead the next generation of targeted drug delivery, creating breakthrough solutions that improve patient outcomes and set new standards in oncology care.
Through Our Science We Are Transforming Cancer Treatment for Chemotherapy Patients
